vs
Side-by-side financial comparison of NIP Group Inc. (NIPG) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $39.3M, roughly 1.8× NIP Group Inc.). NIP Group Inc. runs the higher net margin — -11.9% vs -49.0%, a 37.2% gap on every dollar of revenue.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
NIPG vs VRDN — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.3M | $70.6M |
| Net Profit | $-4.7M | $-34.6M |
| Gross Margin | 6.0% | — |
| Operating Margin | -13.0% | -56.7% |
| Net Margin | -11.9% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.8M | $490.9M |
| Total DebtLower is stronger | $3.8M | — |
| Stockholders' EquityBook value | — | $503.0M |
| Total Assets | $305.3M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q2 24 | $6.8M | — |
| Q3 25 | — | — | ||
| Q2 24 | $3.8M | — |
| Q3 25 | — | $503.0M | ||
| Q2 24 | — | — |
| Q3 25 | — | $577.1M | ||
| Q2 24 | $305.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q2 24 | — | — |
| Q3 25 | — | $-84.7M | ||
| Q2 24 | — | — |
| Q3 25 | — | -120.1% | ||
| Q2 24 | — | — |
| Q3 25 | — | 0.2% | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
